Allurion technologies inc美股招股说明书(2026-01-20版)

Up to 5,988,024 shares of common stock of Allurion Technologies, Inc. (“Allurion”) may be offered for sale by selling securityholders. The offering is subject to a shelf registration statement filed with the U.S. Securities and Exchange Commission (SEC). Allurion will not receive any proceeds from the sale. The proceeds from the exercise of November 2025 Private Placement Warrants, up to approximately $5.0 million, will be used for working capital and general corporate purposes. The company is an emerging growth company and a smaller reporting company, which provides certain exemptions from reporting requirements. Allurion is a medical device company focused on a weight loss platform featuring the Allurion Smart Capsule, a swallowable, procedureless intragastric balloon, and AI-powered remote patient monitoring tools. The Allurion Program aims to achieve metabolically healthy weight loss. Allurion has submitted a premarket application for approval by the U.S. Food and Drug Administration for sale of its Allurion Program in the United States.